FDA Sets Final Potency Rules for Gene Therapies

The guidance requires potency verification across development and post-market stages for cell and gene therapies.

Updated on Nov. 2, 2026 in Biotech

Clean editorial illustration of frosted cryogenic cylinders and a single amber vial on a navy and cream field, evoking batch-level biological verification. — The FDA has issued final guidance requiring cell and gene therapy manufacturers to verify each batch's potency before it reaches patients, replacing its 2011 guidance. AI Illustration. Upload story photo >

The FDA has issued final guidance for cellular and gene therapy manufacturers on potency assurance, replacing its 2011 potency testing guidance. The guidance is final, so it is in effect policy rather than a proposal.

Why it matters

The guidance sets out how manufacturers should verify that each batch of a cellular or gene therapy is biologically active before it reaches a patient, and it covers products for serious, often life-threatening conditions. It signals the agency's push to define potency as a lifecycle requirement, from early investigational submissions through approval and post-market verification.

The evidence is a final FDA guidance document, which carries regulatory weight rather than trial data. The guidance does not publish quantitative potency thresholds in the source, and the exact testing standards are not specified.

The players

U.S. Food and Drug Administration (FDA)

The federal agency that regulates cellular and gene therapy products in the United States and issued the final potency guidance.

The details

Potency refers to how strongly a biological product produces its intended effect. Under the guidance, manufacturers test and verify potency for every batch before a product reaches a patient, and they must confirm products work as intended from approval through post-approval monitoring. The recommendations are flexible and risk-based, covering controls for raw-material variability, in-process testing, and lab assays confirming each batch is biologically active.

November 2, 2026: FDA issues the final guidance on potency assurance.
December 10, 2026: FDA webinar to help stakeholders understand and implement the guidance.

The Tech Race

The guidance updates FDA's framework for a field where gene and cell therapies are advancing rapidly and manufacturing consistency is a central constraint. Replacing the 2011 guidance positions the agency's expectations for these products closer to current development practices.

Manufacturers of cellular and gene therapies must now apply the guidance's potency verification approach to their products. Patients receiving these treatments should see the effect only indirectly, as the agency sets expectations for batch-level verification; the source gives no timeline for specific therapies.

The takeaway

Potency verification is becoming a lifecycle requirement for gene and cell therapies rather than a release-time check. Watch the December 10, 2026 FDA webinar for implementation details on the testing standards.